Page last updated: 2024-11-06

rp 31264

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

suriclone: recognizes receptors labeled by benzodiazepines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40903
CHEMBL ID2105561
SCHEMBL ID114688
MeSH IDM0112946

Synonyms (32)

Synonym
suril
31264-rp
rp-31264
suriclone
suriclonum [inn-latin]
rp 31264
suriclona [inn-spanish]
suriclon [inn-french]
4-methyl-1-piperazinecarboxylic acid ester with (+-)-6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-hydroxy-5h-p-dithiino(2,3-c)pyrrol-5-one
einecs 258-794-1
(r,s)-6-(7-chlor-1,8-naphthyridin-2-yl)-3,5,6,7-tetrahydro-5-oxo-2h-(1,4)dithixino(2,3-c)pyrrol-7-yl-4-methyl-1-piperazinylcarboxylat
[6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2h-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate
CHEMBL2105561
celexane
suriclone [inn:ban]
suriclona
suriclonum
53813-83-5
unii-lnc9g689vr
lnc9g689vr ,
suriclon
SCHEMBL114688
1-piperazinecarboxylic acid, 4-methyl-, 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5h-1,4-dithiino(2,3-c)pyrrol-5-yl ester
104355-41-1
suriclone [mi]
suriclone [mart.]
suriclone [inn]
6-(7-chloro-1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-5h-[1,4]dithiino[2,3-c]pyrrol-5-yl 4-methylpiperazine-1-carboxylate
Q7646277
celexane; rp 31264; suriclone
DTXSID20866362
AKOS040749583

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Informal comparisons of the pharmacokinetic data from this study with studies in younger volunteers showed a 53% decrease in clearance and an 84% increase in elimination half-life."( The pharmacokinetics of suriclone after single- and multiple-dose administration in healthy elderly volunteers.
Ankier, SI; Chevalier, P; Crome, P; Dowell, P; Guillet, P; Wijayawardhana, P,
)
0.13
" Pharmacokinetic investigations by radioimmunoassay showed a dose-dependent fast rise of plasma concentrations with a peak at 1 h and a rapid decline thereafter."( Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.
Anderer, P; Chwatal, K; Grünberger, J; Linzmayer, L; Saletu, B; Semlitsch, HV, 1994
)
0.29
" Suriclone AUC, Cmax and Tmax were not affected by imipramine, and reciprocally."( Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man.
Bouquet, S; Chakroun, H; Chapelle, G; Chevalier, P; Gaillot, J; Guillet, P; Montay, G; Perault, MC; Vandel, B, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
"Healthy elderly people aged 70 or more should receive a starting dosage of the anxiolytic drug suriclone half that recommended for younger people; frail or ill elderly people may require further dosage reduction."( The pharmacokinetics of suriclone after single- and multiple-dose administration in healthy elderly volunteers.
Ankier, SI; Chevalier, P; Crome, P; Dowell, P; Guillet, P; Wijayawardhana, P,
)
0.13
" Compared to placebo, no significant effects of the low and middle doses of suriclone on N1 amplitude were observed; the highest dosage reduced N1 amplitude, as did 1 mg alprazolam to an even greater extent."( Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects.
Anderer, P; Saletu, B; Semlitsch, HV, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (60.53)18.7374
1990's15 (39.47)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.34 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (36.59%)5.53%
Reviews1 (2.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (60.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]